Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2013 Financial Results on May 2, 2013
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will
host a conference call and live webcast to report its first quarter 2013
financial results on Thursday, May 2 at 8:30 a.m. ET.
To participate in the conference call, please dial 866-713-8563
(domestic) or 617-597-5311 (international) and reference the access code
86715243. The presentation will be available via a live webcast on the
Investors section of www.acorda.com.
Please log in approximately 5 minutes before the scheduled time of the
presentation to ensure a timely connection.
A replay of the call will be available from 10:30 a.m. ET on May 2, 2013
until midnight on May 30, 2013. To access the replay, please dial
888-286-8010 (domestic) or 617-801-6888 (international) and reference
the access code 81142086. An archived version of the webcast will be
available for 30 days in the Investor Relations section of the Acorda
website at www.acorda.com.
About Acorda
Therapeutics
Acorda Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with MS,
spinal cord injury and other neurological conditions.
Acorda markets AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, in the United
States as a treatment to improve walking in patients with multiple
sclerosis (MS). This was demonstrated by an improvement in walking
speed. AMPYRA is marketed outside the United States as FAMPYRA®
(prolonged-release fampridine tablets) by Biogen Idec under a licensing
agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license
from Alkermes Pharma Ireland Limited.
The Company also markets ZANAFLEX
CAPSULES® (tizanidine hydrochloride) and Zanaflex
tablets, a short-acting drug for the management of spasticity. Acorda
also receives sales royalties on tizanidine hydrochloride capsules, an
authorized generic version of ZANAFLEX CAPSULES, distributed by Actavis,
Inc. under its agreement with Acorda.
Acorda has one of the leading pipelines in the industry of novel
neurological therapies. The Company is developing Diazepam Nasal Spray
for treatment of certain epileptic seizures. It is also studying AMPYRA
to improve a range of functional impairments caused by MS, as well as
its potential for use in other neurological conditions, including
cerebral palsy and post-stroke deficits. In addition, Acorda is
developing clinical stage compounds AC105 for acute treatment of spinal
cord injury, GGF2 for treatment of heart failure and rHIgM22, a
remyelinating monoclonal antibody, for the treatment of MS. GGF2 is also
being investigated in preclinical studies as a treatment for
neurological conditions such as stroke and spinal cord injury.
Chondroitinase, an enzyme that encourages nerve plasticity in spinal
cord injury, is in preclinical development.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including our ability to successfully market and sell Ampyra in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including Diazepam Nasal Spray or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully market
Diazepam Nasal Spray or other products under development; the occurrence
of adverse safety events with our products; delays in obtaining or
failure to obtain regulatory approval of or to successfully market
Fampyra outside of the U.S. and our dependence on our collaboration
partner Biogen Idec in connection therewith; competition, including the
impact of generic competition on Zanaflex Capsules revenues; failure to
protect our intellectual property, to defend against the intellectual
property claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; failure to
comply with regulatory requirements could result in adverse action by
regulatory agencies; and the ability to obtain additional financing to
support our operations. These and other risks are described in greater
detail in Acorda Therapeutics' filings with the Securities & Exchange
Commission. Acorda may not actually achieve the goals or plans described
in its forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in this
release are made only as of the date hereof, and Acorda disclaims any
intent or obligation to update any forward-looking statements as a
result of developments occurring after the date of this release.
